Results 131 to 140 of about 2,067 (154)

Onasemnogene-abeparvovec

Reactions Weekly, 2021
  +4 more sources

Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy

CNS Drugs, 2022
Onasemnogene abeparvovec (Zolgensma®) is a gene therapy approved for the treatment of spinal muscular atrophy (SMA). Administered as a one-time intravenous infusion, onasemnogene abeparvovec uses the adeno-associated virus vector to deliver a functional copy of the human survival motor neuron (SMN) gene to motor neuron cells.
openaire   +2 more sources

Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy

Journal of Hepatology, 2021
Hugh J. McMillan, Sitra Tauscher-Wisniewski, Aaron Kleyn   +2 more
exaly  

Onasemnogene-abeparvovec/prednisolone

Reactions Weekly, 2022
openaire   +2 more sources

Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy

Brain and Development, 2022
Anna Cho, Lee Seungbok, Soo Yeon Kim
exaly  

Current Medical Research and Opinion

Current Medical Research and Opinion, 2021
Chakrapani Balijepalli, Eric Druyts, Matthias Bischof   +2 more
exaly  

Nusinersen/onasemnogene abeparvovec

Reactions Weekly, 2022
openaire   +1 more source

Anakinra/onasemnogene abeparvovec

Reactions Weekly, 2023
openaire   +1 more source

Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec

Sleep Medicine, 2023
Carla Zingariello, Barbara K Smith, Byrne Barry   +2 more
exaly  

Onasemnogene-abeparvovec/prednisone

Reactions Weekly, 2022
openaire   +1 more source